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Our experience of surgical treatment of small-cell lung cancer
Jackevicius, Algirdas K.; Cicenas, S;. Askinis, R.; Pipiriene-Zelviene, 
J.; Mickevicius, R. 
Institute of Oncology Vilnius University, Vilnius, Lithuania
Objective: to analyse the follow-up results of treatment of small-cell 
lung cancer (SCLC) during period 1980-2005 years. There are many 
controversies about the surgical treatment of SCLC.On the other hand, 
other authors report a survival of 33% of ﬁve years in the ﬁrst stage of 
the disease.
Materials and Methods: In Thoracic Clinic of Institute of Oncology 
Vilnius University 2640 patients (pts) with lung cancer were treated 
surgicaly in the course of 1980-2005 years. In 220 cases small- cell 
lung cancer was diagnosed. The distribution of pts according to 
TNM classiﬁcation were: 6 pts had T1N0M0, 36pts- T2N0M0, 10pts 
- T3N0M0, 48pts - T1-2N1M0,12pts - T3N1M0, 60pts - T1,2N2M0, 
5 pts- T4N1M0, 28pts - T4N2M0, in 15 pts distant metastases were 
detected after operation. The most common operation was lobectomy 
which have performed 79 pts, pneumonectomy - 55, bilobectomy -26, 
segmentectomy, wedge resection-6 and in 54 cases was performed only 
explorative thoracotomy. In 4 cases tumor was removed during VATS 
surgery. 177 pts have received additional treatment (chemotherapy, 
radiotherapy), before surgery 50 pts and after operation -129. Some pts 
have received both methods of conservative treatment
The satisfactory results were received in early stages of the disease, 
who were underwent lobectomy and received adjuvant therapy: median 
survival was 35.6 months. The pts after pneumonectomy lived 22.2 
months.
Conclusions: 
1. The surgical treatment could perform only in cases of early stages 
(I-II) of small- cell lung cancer.
2. After operation intensive adjuvant chemotherapy(5-6 cycles) must 
be used in all cases (N0 and N+). The pts with N2 after chemothera-
py must be treated with radiotherapy.
3. The staging of the tumor before surgery during surgical intervention 
is most important factor for suitabale treatment of pts with small- 
cell lung cancer
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Exploration of multidisciplinary therapy including surgery in 
Limited Disease (LD) stage small cell lung cancer (SCLC): a 
clinical report of 122 cases from single institute
Shi, Yuankai1 Wang, Huijie2 Sun, Kelin2 Zhang, Xiangru2 Sun, Yan1 
1 ASCO, Beijing, China 2 CSCO, Beijing, China 
Backgroud: Small cell lung cancer (SCLC) is a systemic disease 
which is rarely cured with surgical resection. At present, Surgery alone 
for SCLC is no longer used as standard therapy; standard management 
of SCLC has included chemotherapy or chemotherapy combined with 
irradiation. The role of surgery remains uncertain,However, Several 
studys revealed that surgery could improved outcome of Limited 
disease SCLC.
Methods: To explore the survival outcome of LD SCLC treated with 
multidisciplinary therapy including surgery. Patients with LD stage 
SCLC treated with multidisciplinary therapy including surgery were 
reviewed retrospectively.
Results: Between Jan 1999 and Dec 2004, 122 patients(pts) SCLC 
treated with multidisciplinary therapy including surgery: male 98, 
female 23; medium age 57(32-81); Pneumonectomy 40 pts, lobectomy 
97 pts and limited resection 3 pts; R0 resection 96 pts, R1 resection 
16 pts and palliative resection 11 pts. Postoperative stage: stage IA 4 
pts,stage IB 25 pts, stage IIB 25, stage IIIA 52 pts and stage IIIB 16 
pts. Two pts died within 1 month after operation, 4 pts treated with 
surgery alone, 2 only received surgery and postoperative radiation, 
3 pts received chemotherapy followed by surgery and postoperative 
chemotherapy (CT+S+CT), 92 pts surgery followed by postoperative 
chemotherapy,and 19 received surgery followed by combined chemo-
radiation. Median survival time (MST) of overall patients is 38 months, 
the 1-,3-,5 year survival rate was 83.6%, 50.0%, and 38.0%, respec-
tively. For 4 pts treated surgery alone, survival time was 13,13.5, 60+ 
and 71+ months respectively, survival time of pts treated with post-
operative radiation alone were 10 and 40+ months, the survival time 
of pts treated with CT+S+CT was 7.7, 47 and 26+ months. For 92 pts 
received postoperative chemotherapy and 19 patients received postop-
erative chemoradiotherapy, the MST was 40.6 months and 28 months, 
5 year survival rate was 38.2% and 40.5%, respectively. According 
to TNM stage system,the MST of stage IA and IB were not reached, 
for stage IIB, IIIA and IIIB was 52 months, 22 months and 13 months 
(P=0.007), respectively. 
Conclusion: Our data showed that LD stage SCLC treated with mul-
tidisciplinary therapy had better survival time, and surgery may play 
more important role in the management of LD stage SCLC. 
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Objective: In 2002, the Thoracic Oncology Advocacy Program at H. 
Lee Mofﬁtt Cancer Center and Research Institute was created with 
a mission to contribute to the prevention and cure of lung cancer by 
embracing the patient perspective. In an effort to increase awareness of 
clinical trials and to humanize the clinical trial process, members of the 
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advocacy program were involved in the creation of the Faces of Lung 
Cancer project. 
Methods: A previous project collected data from newly diagnosed and 
established patients as well as former clinical trial participants on their 
attitudes towards clinical trials for lung cancer patients. Results of this 
project indicated patients held misperceptions about clinical trials and 
their purpose. These data were collected and analyzed using a social 
marketing approach and the resultant intervention was a series of media 
products. The marketing mix for the intervention was reﬁned and based 
upon the narratives of eleven lung cancer patients who participated in 
a clinical trial, ﬁve caregivers of patients who had been on a trial, and 
four thoracic health care professionals. These individuals were inter-
viewed and photographed by a professional photographer with prior 
experience in photo-documentary work. 
Results: The ﬁnal media products include a framed photo exhibit, 
book, brochure, website (www.facesoﬂungcancer.com) and profes-
sional presentation. The book and photo exhibit are continuously 
evaluated for impact and satisfaction. Presently, results indicate the 
process of participating in the Faces of Lung Cancer project has had 
a positive impact on the lives of cancer patients and their caregivers. 
From the 90 evaluations received thus far, respondents agreed that lung 
cancer patients and their loved ones would beneﬁt from the project (M 
= 4.80, SD = 0.41), the essays were easy to read (M = 4.84, SD = 0.37), 
the Faces of Lung Cancer photo essay is a powerful tool for commu-
nicating important information (M = 4.80, SD = 0.41), and they would 
recommend the Faces of Lung Cancer exhibit to people they know (M 
= 4.88, 0.33). 
Conclusion: Evaluation of the Faces of Lung Cancer project indicates 
it is viewed as successful in terms of conveying a message of hope 
and increasing awareness. By including visual displays, in conjunction 
with patient interviews, the photo essay is able to generate and blend 
powerful information and images that provide a richer, more complete 
portrayal of the context of a patient’s experience.
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OASIS, a prospective observation study of treatment of 
chemotherapy-induced anaemia with every 3 weeks Darbepoetin 
alfa
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Introduction: According to several guidelines, Erythropoietic-Stimu-
lating Agents (ESAs) are indicated for treatment of chemotherapy-
induced anaemia (CIA), because they effectively increase haemoglo-
bin (Hb) concentrations, reduce the need for red blood cell (RBC) 
transfusions and improve quality-of-life. Darbepoetin alfa (DA), an 
ESA with a prolonged half-life, has been shown to be effective when 
administered in a dose of 500 ìg once every 3 weeks (Q3W), thereby 
allowing synchronisation of erythropoietic therapy with Q3W chemo-
therapy schedules [Canon et al, J Natl Cancer Inst 98: 273, 2006]. The 
aim of this study was to examine the pattern of use of DA Q3W in daily 
practice in Belgium and Luxembourg, and the adherence to guidelines 
in ESA treatment.
Methods: OASIS (Observational Aranesp® Survey to Investigate the 
q3w Schedule) was a nationwide, prospective observation of DA use 
in 41 oncology centres between April 2005 and January 2006. Adult 
patients with non-myeloid malignancies, who had received DA for CIA 
were included. Data on demographics, type of chemotherapy, baseline 
and evolution of Hb, occurrence of blood transfusion(s), timing of ad-
ministration of the chemotherapy and DA, tolerance and comfort of use 
were collected. Patients were followed from the start of ESA till one 
week after the last DA treatment, with a maximum of 16 weeks.
Results: 293 patients were included. Mean age was 63 years (range 
25-89), 51% were male, 263 patients had a solid tumour (NSCLC 
n=91; breast cancer n=64; and SCLC n=32; others n=76) and 30 had 
haematologic malignancies. 30.8% were non-metastatic tumours, 
62.4% were metastatic, and 6.8% were recurrent. 57% of patients had 
platinum containing chemotherapy (mainly lung cancer). Baseline Hb 
was between 10 and 11 g/dL in 50.9% of the patients, and between 9 
and 10 g/dL in 31.1%. In an analysis correcting for RBC transfusion 
(disregarding Hb values after ﬁrst transfusion), the crude haematopoi-
etic response rate was 53.6% in platinum treated patients, compared 
to 47.1% in non-platinum treated patients. A Hb level of 11 g/dL was 
reached in 68% of the patients (both platinum and non-platinum). The 
RBC transfusion rate was 26.6%, similar in platinum or non-platinum 
treated patients. 63.4% of the patients experienced a very good to 
satisfactory improvement of anemia related symptoms. The majority 
of the patients (69.6%) were treated in a Q3W chemotherapy schedule. 
The DA Q3W interval could be maintained in a substantial number of 
patients. The most important reason for not respecting the Q3W DA in-
terval was practical (mainly remain synchronized with chemotherapy). 
There were no unexpected safety concerns, with only 7 adverse and 3 
serious adverse events.
Conclusion: This prospective observation study conﬁrms the phase III 
study efﬁcacy and safety ﬁndings of Canon et al. in a broader commu-
nity setting. Adherence to guidelines is good, as ESA therapy is indeed 
started at a Hb threshold between 9 and 11 g/dL in more than 80% of 
the patients. The synchronisation of ESA therapy could be maintained 
in a substantial number of patients.
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Healthcare Assessment Methodology in Developing Country
Bohara, Amrit B. 
Community Health and Environmental Society Nepal, Kathmandu, 
Nepal
Objective: To validate the Rapid Community Health Assessment 
Methodology (RCHA) for prioritization of community health problems 
(Eg: Tobacco And Cancer Control) in a rural community. 
Methods: 14 Villages of rural areas. Study Population: 34 Primary 
School Teachers from 10 randomly selected Primary Schools in 
above villages. (One Teacher each from Class I to V, in each School). 
Validation: Heads of households from 500 Households (50 per village, 
systematically sampled). DATA Self-Administered Questionnaires for 
Teachers, Interview Schedules for Heads of Households. Data Analy-
sis: with the help of EPI info program. 
Results: There was signiﬁcant correlation between the responses of 
the school teachers and heads of households on community health 
problems viz., (a) the prioritization of ten village problems(r=+0.77, 
